What does the future hold? I've been wondering if some form of a deal could happen which has milestone payments that allow the science (papers & trials) some more time to prove what the drug can do across more indications, that then leads to an option for either licensing or a buyout.

I suppose offers to make deals can come in at any time, but at some point when there is clinical data showing clearly that the platform drug thing is real, it is IMO going to get very interesting. It seems likely that this weeks investor call might tell us more about the next steps in our path.

I've listed a few links below which I found interesting that summarize various types of deals. The first link has an easy to view matrix of what indications various pharmas were looking to tap into via deals.

2021 https://www.alacrita.com/whitepapers/pharma-l...d-wishlist

2023 https://www.jpmorgan.com/content/dam/jpmorgan...report.pdf

2024 https://www.ropesgray.com/en/insights/alerts/...nd-outlook